Illinois General Assembly - Full Text of Public Act 100-0799
Illinois General Assembly

Previous General Assemblies

Public Act 100-0799


 

Public Act 0799 100TH GENERAL ASSEMBLY

  
  
  

 


 
Public Act 100-0799
 
SB2889 EnrolledLRB100 19109 MJP 34369 b

    AN ACT concerning health.
 
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
 
    Section 5. The School Code is amended by changing Section
22-30 as follows:
 
    (105 ILCS 5/22-30)
    Sec. 22-30. Self-administration and self-carry of asthma
medication and epinephrine injectors auto-injectors;
administration of undesignated epinephrine injectors
auto-injectors; administration of an opioid antagonist; asthma
episode emergency response protocol.
    (a) For the purpose of this Section only, the following
terms shall have the meanings set forth below:
    "Asthma action plan" means a written plan developed with a
pupil's medical provider to help control the pupil's asthma.
The goal of an asthma action plan is to reduce or prevent
flare-ups and emergency department visits through day-to-day
management and to serve as a student-specific document to be
referenced in the event of an asthma episode.
    "Asthma episode emergency response protocol" means a
procedure to provide assistance to a pupil experiencing
symptoms of wheezing, coughing, shortness of breath, chest
tightness, or breathing difficulty.
    "Asthma inhaler" means a quick reliever asthma inhaler.
    "Epinephrine auto-injector" means a single-use device used
for the automatic injection of a pre-measured dose of
epinephrine into the human body.
    "Epinephrine injector" includes an auto-injector approved
by the United States Food and Drug Administration for the
administration of epinephrine and a pre-filled syringe
approved by the United States Food and Drug Administration and
used for the administration of epinephrine that contains a
pre-measured dose of epinephrine that is equivalent to the
dosages used in an auto-injector.
    "Asthma medication" means a medicine, prescribed by (i) a
physician licensed to practice medicine in all its branches,
(ii) a licensed physician assistant with prescriptive
authority, or (iii) a licensed advanced practice registered
nurse with prescriptive authority for a pupil that pertains to
the pupil's asthma and that has an individual prescription
label.
    "Opioid antagonist" means a drug that binds to opioid
receptors and blocks or inhibits the effect of opioids acting
on those receptors, including, but not limited to, naloxone
hydrochloride or any other similarly acting drug approved by
the U.S. Food and Drug Administration.
    "School nurse" means a registered nurse working in a school
with or without licensure endorsed in school nursing.
    "Self-administration" means a pupil's discretionary use of
his or her prescribed asthma medication or epinephrine injector
auto-injector.
    "Self-carry" means a pupil's ability to carry his or her
prescribed asthma medication or epinephrine injector
auto-injector.
    "Standing protocol" may be issued by (i) a physician
licensed to practice medicine in all its branches, (ii) a
licensed physician assistant with prescriptive authority, or
(iii) a licensed advanced practice registered nurse with
prescriptive authority.
    "Trained personnel" means any school employee or volunteer
personnel authorized in Sections 10-22.34, 10-22.34a, and
10-22.34b of this Code who has completed training under
subsection (g) of this Section to recognize and respond to
anaphylaxis.
    "Undesignated epinephrine injector auto-injector" means an
epinephrine injector auto-injector prescribed in the name of a
school district, public school, or nonpublic school.
    (b) A school, whether public or nonpublic, must permit the
self-administration and self-carry of asthma medication by a
pupil with asthma or the self-administration and self-carry of
an epinephrine injector auto-injector by a pupil, provided
that:
        (1) the parents or guardians of the pupil provide to
    the school (i) written authorization from the parents or
    guardians for (A) the self-administration and self-carry
    of asthma medication or (B) the self-carry of asthma
    medication or (ii) for (A) the self-administration and
    self-carry of an epinephrine injector auto-injector or (B)
    the self-carry of an epinephrine injector auto-injector,
    written authorization from the pupil's physician,
    physician assistant, or advanced practice registered
    nurse; and
        (2) the parents or guardians of the pupil provide to
    the school (i) the prescription label, which must contain
    the name of the asthma medication, the prescribed dosage,
    and the time at which or circumstances under which the
    asthma medication is to be administered, or (ii) for the
    self-administration or self-carry of an epinephrine
    injector auto-injector, a written statement from the
    pupil's physician, physician assistant, or advanced
    practice registered nurse containing the following
    information:
            (A) the name and purpose of the epinephrine
        injector auto-injector;
            (B) the prescribed dosage; and
            (C) the time or times at which or the special
        circumstances under which the epinephrine injector
        auto-injector is to be administered.
The information provided shall be kept on file in the office of
the school nurse or, in the absence of a school nurse, the
school's administrator.
    (b-5) A school district, public school, or nonpublic school
may authorize the provision of a student-specific or
undesignated epinephrine injector auto-injector to a student
or any personnel authorized under a student's Individual Health
Care Action Plan, Illinois Food Allergy Emergency Action Plan
and Treatment Authorization Form, or plan pursuant to Section
504 of the federal Rehabilitation Act of 1973 to administer an
epinephrine injector auto-injector to the student, that meets
the student's prescription on file.
    (b-10) The school district, public school, or nonpublic
school may authorize a school nurse or trained personnel to do
the following: (i) provide an undesignated epinephrine
injector auto-injector to a student for self-administration
only or any personnel authorized under a student's Individual
Health Care Action Plan, Illinois Food Allergy Emergency Action
Plan and Treatment Authorization Form, or plan pursuant to
Section 504 of the federal Rehabilitation Act of 1973 to
administer to the student, that meets the student's
prescription on file; (ii) administer an undesignated
epinephrine injector auto-injector that meets the prescription
on file to any student who has an Individual Health Care Action
Plan, Illinois Food Allergy Emergency Action Plan and Treatment
Authorization Form, or plan pursuant to Section 504 of the
federal Rehabilitation Act of 1973 that authorizes the use of
an epinephrine injector auto-injector; (iii) administer an
undesignated epinephrine injector auto-injector to any person
that the school nurse or trained personnel in good faith
believes is having an anaphylactic reaction; and (iv)
administer an opioid antagonist to any person that the school
nurse or trained personnel in good faith believes is having an
opioid overdose.
    (c) The school district, public school, or nonpublic school
must inform the parents or guardians of the pupil, in writing,
that the school district, public school, or nonpublic school
and its employees and agents, including a physician, physician
assistant, or advanced practice registered nurse providing
standing protocol or prescription for school epinephrine
injectors auto-injectors, are to incur no liability or
professional discipline, except for willful and wanton
conduct, as a result of any injury arising from the
administration of asthma medication, an epinephrine injector
auto-injector, or an opioid antagonist regardless of whether
authorization was given by the pupil's parents or guardians or
by the pupil's physician, physician assistant, or advanced
practice registered nurse. The parents or guardians of the
pupil must sign a statement acknowledging that the school
district, public school, or nonpublic school and its employees
and agents are to incur no liability, except for willful and
wanton conduct, as a result of any injury arising from the
administration of asthma medication, an epinephrine injector
auto-injector, or an opioid antagonist regardless of whether
authorization was given by the pupil's parents or guardians or
by the pupil's physician, physician assistant, or advanced
practice registered nurse and that the parents or guardians
must indemnify and hold harmless the school district, public
school, or nonpublic school and its employees and agents
against any claims, except a claim based on willful and wanton
conduct, arising out of the administration of asthma
medication, an epinephrine injector auto-injector, or an
opioid antagonist regardless of whether authorization was
given by the pupil's parents or guardians or by the pupil's
physician, physician assistant, or advanced practice
registered nurse.
    (c-5) When a school nurse or trained personnel administers
an undesignated epinephrine injector auto-injector to a person
whom the school nurse or trained personnel in good faith
believes is having an anaphylactic reaction or administers an
opioid antagonist to a person whom the school nurse or trained
personnel in good faith believes is having an opioid overdose,
notwithstanding the lack of notice to the parents or guardians
of the pupil or the absence of the parents or guardians signed
statement acknowledging no liability, except for willful and
wanton conduct, the school district, public school, or
nonpublic school and its employees and agents, and a physician,
a physician assistant, or an advanced practice registered nurse
providing standing protocol or prescription for undesignated
epinephrine injectors auto-injectors, are to incur no
liability or professional discipline, except for willful and
wanton conduct, as a result of any injury arising from the use
of an undesignated epinephrine injector auto-injector or the
use of an opioid antagonist regardless of whether authorization
was given by the pupil's parents or guardians or by the pupil's
physician, physician assistant, or advanced practice
registered nurse.
    (d) The permission for self-administration and self-carry
of asthma medication or the self-administration and self-carry
of an epinephrine injector auto-injector is effective for the
school year for which it is granted and shall be renewed each
subsequent school year upon fulfillment of the requirements of
this Section.
    (e) Provided that the requirements of this Section are
fulfilled, a pupil with asthma may self-administer and
self-carry his or her asthma medication or a pupil may
self-administer and self-carry an epinephrine injector
auto-injector (i) while in school, (ii) while at a
school-sponsored activity, (iii) while under the supervision
of school personnel, or (iv) before or after normal school
activities, such as while in before-school or after-school care
on school-operated property or while being transported on a
school bus.
    (e-5) Provided that the requirements of this Section are
fulfilled, a school nurse or trained personnel may administer
an undesignated epinephrine injector auto-injector to any
person whom the school nurse or trained personnel in good faith
believes to be having an anaphylactic reaction (i) while in
school, (ii) while at a school-sponsored activity, (iii) while
under the supervision of school personnel, or (iv) before or
after normal school activities, such as while in before-school
or after-school care on school-operated property or while being
transported on a school bus. A school nurse or trained
personnel may carry undesignated epinephrine injectors
auto-injectors on his or her person while in school or at a
school-sponsored activity.
    (e-10) Provided that the requirements of this Section are
fulfilled, a school nurse or trained personnel may administer
an opioid antagonist to any person whom the school nurse or
trained personnel in good faith believes to be having an opioid
overdose (i) while in school, (ii) while at a school-sponsored
activity, (iii) while under the supervision of school
personnel, or (iv) before or after normal school activities,
such as while in before-school or after-school care on
school-operated property. A school nurse or trained personnel
may carry an opioid antagonist on their person while in school
or at a school-sponsored activity.
    (f) The school district, public school, or nonpublic school
may maintain a supply of undesignated epinephrine injectors
auto-injectors in any secure location that is accessible
before, during, and after school where an allergic person is
most at risk, including, but not limited to, classrooms and
lunchrooms. A physician, a physician assistant who has been
delegated prescriptive authority in accordance with Section
7.5 of the Physician Assistant Practice Act of 1987, or an
advanced practice registered nurse who has been delegated
prescriptive authority in accordance with Section 65-40 of the
Nurse Practice Act may prescribe undesignated epinephrine
injectors auto-injectors in the name of the school district,
public school, or nonpublic school to be maintained for use
when necessary. Any supply of epinephrine injectors
auto-injectors shall be maintained in accordance with the
manufacturer's instructions.
    The school district, public school, or nonpublic school may
maintain a supply of an opioid antagonist in any secure
location where an individual may have an opioid overdose. A
health care professional who has been delegated prescriptive
authority for opioid antagonists in accordance with Section
5-23 of the Alcoholism and Other Drug Abuse and Dependency Act
may prescribe opioid antagonists in the name of the school
district, public school, or nonpublic school, to be maintained
for use when necessary. Any supply of opioid antagonists shall
be maintained in accordance with the manufacturer's
instructions.
    (f-3) Whichever entity initiates the process of obtaining
undesignated epinephrine injectors auto-injectors and
providing training to personnel for carrying and administering
undesignated epinephrine injectors auto-injectors shall pay
for the costs of the undesignated epinephrine injectors
auto-injectors.
    (f-5) Upon any administration of an epinephrine injector
auto-injector, a school district, public school, or nonpublic
school must immediately activate the EMS system and notify the
student's parent, guardian, or emergency contact, if known.
    Upon any administration of an opioid antagonist, a school
district, public school, or nonpublic school must immediately
activate the EMS system and notify the student's parent,
guardian, or emergency contact, if known.
    (f-10) Within 24 hours of the administration of an
undesignated epinephrine injector auto-injector, a school
district, public school, or nonpublic school must notify the
physician, physician assistant, or advanced practice
registered nurse who provided the standing protocol or
prescription for the undesignated epinephrine injector
auto-injector of its use.
    Within 24 hours after the administration of an opioid
antagonist, a school district, public school, or nonpublic
school must notify the health care professional who provided
the prescription for the opioid antagonist of its use.
    (g) Prior to the administration of an undesignated
epinephrine injector auto-injector, trained personnel must
submit to their school's administration proof of completion of
a training curriculum to recognize and respond to anaphylaxis
that meets the requirements of subsection (h) of this Section.
Training must be completed annually. The school district,
public school, or nonpublic school must maintain records
related to the training curriculum and trained personnel.
    Prior to the administration of an opioid antagonist,
trained personnel must submit to their school's administration
proof of completion of a training curriculum to recognize and
respond to an opioid overdose, which curriculum must meet the
requirements of subsection (h-5) of this Section. Training must
be completed annually. Trained personnel must also submit to
the school's administration proof of cardiopulmonary
resuscitation and automated external defibrillator
certification. The school district, public school, or
nonpublic school must maintain records relating to the training
curriculum and the trained personnel.
    (h) A training curriculum to recognize and respond to
anaphylaxis, including the administration of an undesignated
epinephrine injector auto-injector, may be conducted online or
in person.
    Training shall include, but is not limited to:
        (1) how to recognize signs and symptoms of an allergic
    reaction, including anaphylaxis;
        (2) how to administer an epinephrine injector
    auto-injector; and
        (3) a test demonstrating competency of the knowledge
    required to recognize anaphylaxis and administer an
    epinephrine injector auto-injector.
    Training may also include, but is not limited to:
        (A) a review of high-risk areas within a school and its
    related facilities;
        (B) steps to take to prevent exposure to allergens;
        (C) emergency follow-up procedures;
        (D) how to respond to a student with a known allergy,
    as well as a student with a previously unknown allergy; and
        (E) other criteria as determined in rules adopted
    pursuant to this Section.
    In consultation with statewide professional organizations
representing physicians licensed to practice medicine in all of
its branches, registered nurses, and school nurses, the State
Board of Education shall make available resource materials
consistent with criteria in this subsection (h) for educating
trained personnel to recognize and respond to anaphylaxis. The
State Board may take into consideration the curriculum on this
subject developed by other states, as well as any other
curricular materials suggested by medical experts and other
groups that work on life-threatening allergy issues. The State
Board is not required to create new resource materials. The
State Board shall make these resource materials available on
its Internet website.
    (h-5) A training curriculum to recognize and respond to an
opioid overdose, including the administration of an opioid
antagonist, may be conducted online or in person. The training
must comply with any training requirements under Section 5-23
of the Alcoholism and Other Drug Abuse and Dependency Act and
the corresponding rules. It must include, but is not limited
to:
        (1) how to recognize symptoms of an opioid overdose;
        (2) information on drug overdose prevention and
    recognition;
        (3) how to perform rescue breathing and resuscitation;
        (4) how to respond to an emergency involving an opioid
    overdose;
        (5) opioid antagonist dosage and administration;
        (6) the importance of calling 911;
        (7) care for the overdose victim after administration
    of the overdose antagonist;
        (8) a test demonstrating competency of the knowledge
    required to recognize an opioid overdose and administer a
    dose of an opioid antagonist; and
        (9) other criteria as determined in rules adopted
    pursuant to this Section.
    (i) Within 3 days after the administration of an
undesignated epinephrine injector auto-injector by a school
nurse, trained personnel, or a student at a school or
school-sponsored activity, the school must report to the State
Board of Education in a form and manner prescribed by the State
Board the following information:
        (1) age and type of person receiving epinephrine
    (student, staff, visitor);
        (2) any previously known diagnosis of a severe allergy;
        (3) trigger that precipitated allergic episode;
        (4) location where symptoms developed;
        (5) number of doses administered;
        (6) type of person administering epinephrine (school
    nurse, trained personnel, student); and
        (7) any other information required by the State Board.
    If a school district, public school, or nonpublic school
maintains or has an independent contractor providing
transportation to students who maintains a supply of
undesignated epinephrine injectors auto-injectors, then the
school district, public school, or nonpublic school must report
that information to the State Board of Education upon adoption
or change of the policy of the school district, public school,
nonpublic school, or independent contractor, in a manner as
prescribed by the State Board. The report must include the
number of undesignated epinephrine injectors auto-injectors in
supply.
    (i-5) Within 3 days after the administration of an opioid
antagonist by a school nurse or trained personnel, the school
must report to the State Board of Education, in a form and
manner prescribed by the State Board, the following
information:
        (1) the age and type of person receiving the opioid
    antagonist (student, staff, or visitor);
        (2) the location where symptoms developed;
        (3) the type of person administering the opioid
    antagonist (school nurse or trained personnel); and
        (4) any other information required by the State Board.
    (j) By October 1, 2015 and every year thereafter, the State
Board of Education shall submit a report to the General
Assembly identifying the frequency and circumstances of
epinephrine administration during the preceding academic year.
Beginning with the 2017 report, the report shall also contain
information on which school districts, public schools, and
nonpublic schools maintain or have independent contractors
providing transportation to students who maintain a supply of
undesignated epinephrine injectors auto-injectors. This report
shall be published on the State Board's Internet website on the
date the report is delivered to the General Assembly.
    (j-5) Annually, each school district, public school,
charter school, or nonpublic school shall request an asthma
action plan from the parents or guardians of a pupil with
asthma. If provided, the asthma action plan must be kept on
file in the office of the school nurse or, in the absence of a
school nurse, the school administrator. Copies of the asthma
action plan may be distributed to appropriate school staff who
interact with the pupil on a regular basis, and, if applicable,
may be attached to the pupil's federal Section 504 plan or
individualized education program plan.
    (j-10) To assist schools with emergency response
procedures for asthma, the State Board of Education, in
consultation with statewide professional organizations with
expertise in asthma management and a statewide organization
representing school administrators, shall develop a model
asthma episode emergency response protocol before September 1,
2016. Each school district, charter school, and nonpublic
school shall adopt an asthma episode emergency response
protocol before January 1, 2017 that includes all of the
components of the State Board's model protocol.
    (j-15) Every 2 years, school personnel who work with pupils
shall complete an in-person or online training program on the
management of asthma, the prevention of asthma symptoms, and
emergency response in the school setting. In consultation with
statewide professional organizations with expertise in asthma
management, the State Board of Education shall make available
resource materials for educating school personnel about asthma
and emergency response in the school setting.
    (j-20) On or before October 1, 2016 and every year
thereafter, the State Board of Education shall submit a report
to the General Assembly and the Department of Public Health
identifying the frequency and circumstances of opioid
antagonist administration during the preceding academic year.
This report shall be published on the State Board's Internet
website on the date the report is delivered to the General
Assembly.
    (k) The State Board of Education may adopt rules necessary
to implement this Section.
    (l) Nothing in this Section shall limit the amount of
epinephrine injectors auto-injectors that any type of school or
student may carry or maintain a supply of.
(Source: P.A. 99-173, eff. 7-29-15; 99-480, eff. 9-9-15;
99-642, eff. 7-28-16; 99-711, eff. 1-1-17; 99-843, eff.
8-19-16; 100-201, eff. 8-18-17; 100-513, eff. 1-1-18.)
 
    Section 10. The Epinephrine Auto-Injector Act is amended by
changing Sections 1, 5, 10, 15, and 20 as follows:
 
    (410 ILCS 27/1)
    Sec. 1. Short title. This Act may be cited as the
Epinephrine Injector Auto-Injector Act.
(Source: P.A. 99-711, eff. 1-1-17.)
 
    (410 ILCS 27/5)
    Sec. 5. Definitions. As used in this Act:
    "Administer" means to directly apply an epinephrine
injector auto-injector to the body of an individual.
    "Authorized entity" means any entity or organization,
other than a school covered under Section 22-30 of the School
Code, in connection with or at which allergens capable of
causing anaphylaxis may be present, including, but not limited
to, independent contractors who provide student transportation
to schools, recreation camps, colleges and universities, day
care facilities, youth sports leagues, amusement parks,
restaurants, sports arenas, and places of employment. The
Department shall, by rule, determine what constitutes a day
care facility under this definition.
    "Department" means the Department of Public Health.
    "Epinephrine injector" includes an auto-injector approved
by the United States Food and Drug Administration for the
administration of epinephrine and a pre-filled syringe
approved by the United States Food and Drug Administration and
used for the administration of epinephrine that contains a
pre-measured dose of epinephrine that is equivalent to the
dosages used in an auto-injector.
    "Epinephrine auto-injector" means a single-use device used
for the automatic injection of a pre-measured dose of
epinephrine into the human body.
    "Health care practitioner" means a physician licensed to
practice medicine in all its branches under the Medical
Practice Act of 1987, a physician assistant under the Physician
Assistant Practice Act of 1987 with prescriptive authority, or
an advanced practice registered nurse with prescribing
authority under Article 65 of the Nurse Practice Act.
    "Pharmacist" has the meaning given to that term under
subsection (k-5) of Section 3 of the Pharmacy Practice Act.
    "Undesignated epinephrine injector auto-injector" means an
epinephrine injector auto-injector prescribed in the name of an
authorized entity.
(Source: P.A. 99-711, eff. 1-1-17; 100-513, eff. 1-1-18.)
 
    (410 ILCS 27/10)
    Sec. 10. Prescription to authorized entity; use; training.
    (a) A health care practitioner may prescribe epinephrine
injectors auto-injectors in the name of an authorized entity
for use in accordance with this Act, and pharmacists and health
care practitioners may dispense epinephrine injectors
auto-injectors pursuant to a prescription issued in the name of
an authorized entity. Such prescriptions shall be valid for a
period of 2 years.
    (b) An authorized entity may acquire and stock a supply of
undesignated epinephrine injectors auto-injectors pursuant to
a prescription issued under subsection (a) of this Section.
Such undesignated epinephrine injectors auto-injectors shall
be stored in a location readily accessible in an emergency and
in accordance with the instructions for use of the epinephrine
injectors auto-injectors. The Department may establish any
additional requirements an authorized entity must follow under
this Act.
    (c) An employee or agent of an authorized entity or other
individual who has completed training under subsection (d) of
this Section may:
        (1) provide an epinephrine injector auto-injector to
    any individual on the property of the authorized entity
    whom the employee, agent, or other individual believes in
    good faith is experiencing anaphylaxis, or to the parent,
    guardian, or caregiver of such individual, for immediate
    administration, regardless of whether the individual has a
    prescription for an epinephrine injector auto-injector or
    has previously been diagnosed with an allergy; or
        (2) administer an epinephrine injector auto-injector
    to any individual on the property of the authorized entity
    whom the employee, agent, or other individual believes in
    good faith is experiencing anaphylaxis, regardless of
    whether the individual has a prescription for an
    epinephrine injector auto-injector or has previously been
    diagnosed with an allergy.
    (d) An employee, agent, or other individual authorized must
complete an anaphylaxis training program before he or she is
able to provide or administer an epinephrine injector
auto-injector under this Section. Such training shall be valid
for a period of 2 years and shall be conducted by a nationally
recognized organization experienced in training laypersons in
emergency health treatment. The Department shall include links
to training providers' websites on its website.
    Training shall include, but is not limited to:
        (1) how to recognize signs and symptoms of an allergic
    reaction, including anaphylaxis;
        (2) how to administer an epinephrine injector
    auto-injector; and
        (3) a test demonstrating competency of the knowledge
    required to recognize anaphylaxis and administer an
    epinephrine injector auto-injector.
    Training may also include, but is not limited to:
        (A) a review of high-risk areas on the authorized
    entity's property and its related facilities;
        (B) steps to take to prevent exposure to allergens;
        (C) emergency follow-up procedures; and
        (D) other criteria as determined in rules adopted
    pursuant to this Act.
    Training may be conducted either online or in person. The
Department shall approve training programs and list permitted
training programs on the Department's Internet website.
(Source: P.A. 99-711, eff. 1-1-17.)
 
    (410 ILCS 27/15)
    Sec. 15. Costs. Whichever entity initiates the process of
obtaining undesignated epinephrine injectors auto-injectors
and providing training to personnel for carrying and
administering undesignated epinephrine injectors
auto-injectors shall pay for the costs of the undesignated
epinephrine injectors auto-injectors.
(Source: P.A. 99-711, eff. 1-1-17.)
 
    (410 ILCS 27/20)
    Sec. 20. Limitations. The use of an undesignated
epinephrine injector auto-injector in accordance with the
requirements of this Act does not constitute the practice of
medicine or any other profession that requires medical
licensure.
    Nothing in this Act shall limit the amount of epinephrine
injectors auto-injectors that an authorized entity or
individual may carry or maintain a supply of.
(Source: P.A. 99-711, eff. 1-1-17.)
 
    Section 15. The Illinois Food, Drug and Cosmetic Act is
amended by changing Section 3.21 as follows:
 
    (410 ILCS 620/3.21)  (from Ch. 56 1/2, par. 503.21)
    Sec. 3.21. Except as authorized by this Act, the Illinois
Controlled Substances Act, the Pharmacy Practice Act, the
Dental Practice Act, the Medical Practice Act of 1987, the
Veterinary Medicine and Surgery Practice Act of 2004, the
Podiatric Medical Practice Act of 1987, Section 22-30 of the
School Code, Section 40 of the State Police Act, Section 10.19
of the Illinois Police Training Act, or the Epinephrine
Injector Auto-Injector Act, to sell or dispense a prescription
drug without a prescription.
(Source: P.A. 99-78, eff. 7-20-15; 99-711, eff. 1-1-17.)

Effective Date: 1/1/2019